stockrow
Monday 9 November 2026
Export CNTN’s income statement to Excel — free account
Canton Strategic Holdings, Inc.
CNTN- EPS
- +85.9%
- Free cash flow
- −600.4%
Quarter to June 2026, against a year earlier
2.06
0.13
+6.74%
Follow CNTN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | (2) | (2) | (2) | (8) | (9) | (12) | (42) | (114) | +73.8% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (2) | (2) | (2) | (8) | (9) | (12) | (36) | (98) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (3.70) | (142.75) | (130.10) | (281.11) | (107.05) | (9.41) | (1.12) | (0.91) | (18.1%) | ||||||
| Cash flow | — | — | — | (1.71) | (63.81) | (63.89) | (217.15) | (83.91) | (8.41) | (0.50) | (0.10) | (18.5%) | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.42) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (1.71) | (63.81) | (63.89) | (217.15) | (83.91) | (8.41) | (2.92) | (0.10) | +9.3% | ||||||
| Book value | — | — | — | (3.94) | (219.97) | (275.58) | 183.57 | 104.96 | 1.01 | 12.42 | 2.10 | n/m | ||||||
| Shares, m | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 32 | 116 | +106.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (1) | (1) | (7) | (7) | (11) | (16) | (22) | +68.4% | |||||
| Capex | — | — | — | — | — | — | — | — | — | (78) | — | — | ||||||
| Free cash flow | — | — | — | (1) | (1) | (1) | (7) | (7) | (11) | (94) | (22) | +125.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (1) | (2) | (4) | 6 | 9 | 1 | 14 | 39 | n/m | |||||
| Net debt | — | — | — | 1 | 1 | 1 | (7) | (11) | (4) | (17) | (37) | n/m | ||||||
| Shareholders’ equity | — | — | — | (2) | (4) | (5) | 6 | 9 | 1 | 398 | 455 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (7,459.66) | (1,440.21) | (481.53) | (231.82) | (105.69) | (166.32) | (13.74) | (34.60) | +7,445.9 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3.30) | (8.11) | (3.3) pt | ||||||
| ROE | — | — | — | 57.14 | 90.54 | 52.52 | (1,973.27) | (127.01) | (233.70) | (17.99) | (43.10) | (75.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 2 | 2 | 3 | 3 | 12 | — | +56.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Canton Strategic Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PEPG PepGen, Inc. | $171.1M | — (loss-making) | — | — | n/m | +33.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CNTN Canton Strategic Holdings, Inc. | $164.1M | — (loss-making) | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | |
| IPHA Innate Pharma S.A. Sponsored ADR | $160.9M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ORMP Oramed Pharmaceuticals Inc. | $160.6M | 0.9× | 0.9× | +193.26% (above 0%: growing) | +493.75% (above 0%: growing) | +94.29% (above 0%: growing) | 0.65% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $159.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| STRO Sutro Biopharma, Inc. | $159.5M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| ANTX AN2 Therapeutics, Inc. | $150.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SION Sionna Therapeutics, Inc. | $148.3M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | Compare |
| INO Inovio Pharmaceuticals, Inc. | $125.6M | — (loss-making) | — (loss-making) | −83.19% (below 0%: shrinking) | n/m | +13.41% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $159.6M | — | — | −83.19% | — | +13.98% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 25 June 2026
Ownership
Directors and executive officers, together
3.34%
SBI Middlefield Investment Limited
9.99%
DRW Canton Investments LLC
9.99%
Broadridge Securities Processing Solutions LLC
9.99%
Legacy Worldwide Investments II Ltd.
9.99%
Digital Asset Corp.
9.99%
Entities affiliated with LCV Blockchain Management, LLC
9.99%
CXGL Holdings LP
9.99%
Canton Foundation
9.60%
Tradeweb Markets
9.54%
New Infrastructure LLC
7.92%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement